Please assess the completion status of the following clinical trial:

Trial Title: A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have chronic genotype 1 HCV infection with HCV RNA level \>= 5.0 log10 IU/mL~* Patient has never received treatment for HCV (treatment-naive), relapsed after previous IFN-based therapy (prior relapser) or failed to respond to previous IFN-based therapy (non-responder)~* Patient must be willing to use contraceptive measures from the time of informed consent to 6 months after last dose of study medication.~Exclusion Criteria:~* Co-infection with any other HCV genotype or co-infection with the human immunodeficiency virus (HIV)~* Diagnosed with hepatic cirrhosis or hepatic failure~* A medical condition which is a contraindication to peg-IFN or ribavirin therapy~* History of, or any current medical condition, which could impact the safety of the patient in the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks), followed by PR until Week 24 or Week 48. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
- Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
- Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 (Type: EXPERIMENTAL): Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).